Repligen
Highly Engaged Employees
Highly Engaged EmployeesChemicals & Related Products · Massachusetts, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Seyon St Building 41 1 Ste 100, Waltham,...Phone Number
(781) 250-0111Website
www.repligen.comRevenue
$763.3 MillionStock Symbol
RGENIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
2
1
1
About Repligen
Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen is a bioprocessing-focused life sciences company that is inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs.Explore more
Repligen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Repligen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Repligen has recently received funding, and reach out quickly before it becomes old news!
Click to see if Repligen had a recent Job posting/layoffs
Product Launch: Get notified when Repligen launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Repligen recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Repligen
Repligen, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Repligen is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Repligen has new funding data
Recommended Actions
Reach out to Masked Content who joined Repligen as Masked Content
Find 2 more new buyers
Compare Similar Companies to Repligen
Compare insights from companies similar to Repligen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Repligen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Repligen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Repligen.
Repligen Tech Stack
A closer look at the technologies used by Repligen
Most Recent Scoops
Earnings
Repligen has maintained its full-year 2026 gross margin guidance at approximately 135 basis points of year-over-year expansion, noting that favorable product mix contributed approximately one full percentage point of gross margin expansion in the first half, with mix expected to be a headwind in the second half, resulting in a neutral mix impact for the full year.
Earnings, Forecasting, Finance
Earnings
Repligen has reported that its emerging biotech business grew high teens for a fifth consecutive quarter in Q2 2026, and that new modalities grew close to 10% year-over-year with a strong book-to-bill ratio, with the company noting that ATF order trends represent a potential upside driver toward the upper end of its full-year guidance range.
Earnings, Forecasting, Finance
Earnings
Repligen has reported that its approximately 50% proteins growth in Q2 2026 was driven by three areas: strong performance from its OEM partnership with Purolite, a strong quarter in its Avitide custom ligand and resin portfolio, and strong growth in growth factors, reflecting the successful execution of a protein strategy pivot implemented following the loss of two major OEM deals in prior years.
Partnership, Corporate Strategy
Earnings
Repligen has reported that new modalities grew 9% year-over-year in Q2 2026, excluding the impact of a specific gene therapy headwind, representing the strongest quarter since Q1 2025, with a strong sequential increase across all modalities including continued growth in cell therapy and gene therapy when excluding that specific headwind.
Pharmaceuticals
Earnings
Earnings, Finance, Tax
Repligen News & Media
Repligen Corp (RGEN) Q2 2026 Earnings Call Highlights: Strong Growth and Raised Guidance Amidst ...
Repligen Corp (RGEN) reports robust revenue growth and increased full-year guidance, driven by significant gains in the Proteins segment and APAC region.Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
Repligen Corporation (RGEN) Q2 2026 Earnings Call July 28, 2026 8:00 AM EDTCompany ParticipantsJacob Johnson - Vice President of Investor RelationsOlivier...Repligen Q2 Earnings Call Highlights
Repligen (NASDAQ:RGEN) reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring consumables supported growth. The company also raised its full-year organic revenue growth and adjustedRepligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2026, covering the three-month period ended June 30, 2026. The Company is also providing updated financial guidance for the full year 2026.
Read more news
Top Chemicals & Related Products Companies
See more top companies
Frequently Asked Questions Regarding Repligen
Sign Up For FreeTo access detailed company insights
Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen is a bioprocessing-focused life sciences company that is inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs.... Read More
